4+7 band purchasing for the first time to land the implementation of the industrial chain is constantly adjusting the pharmaceutical enterprises to develop the retail industry
April 16, 2019, the shortage of drug supply guarantee and drug centralized purchasing pilot, medical assistance blowing wind meeting was held. Chen Jinfu, deputy director of the State Medical Security Bureau, introduced that as of April 14, the 4+7 banded procurement varieties had completed 27.31% of the total agreed procurement volume. The quality and supply of the winning drugs have been guaranteed, the usage has exceeded expectations, and the relevant policies have basically been fully implemented, such as pre-payment by the medical insurance, hospital use, and payback, among others.
Since the implementation of the first band purchasing, whether the scope of the future national collection continues to expand has raised concerns.
Meanwhile, with the implementation of the policy, the pharmaceutical industry chain is also constantly adjusting. A pharmaceutical distribution of listed companies said to the "Securities Daily" reporter, 4 + 7 band purchasing mainly for the sale of drugs to the hospital, so it will have an impact on the pharmaceutical distribution.
In addition, "because of the pressure to reduce the price of hospital-oriented varieties, so pharmaceutical companies and distribution companies began to retail." The above company sources told reporters.
Total profit of the pharmaceutical industry continued to grow in February 2019
According to Foresight Industry Research Institute released the China Pharmaceutical Industry Market Outlook and Investment Strategy Planning Analysis Report, statistics show that, as of the end of February 2019, China's pharmaceutical industry above scale The number of enterprises reached 7,296, of which the number of loss-making enterprises was 1,696, with a loss surface of 23.2%, an increase of 8.8 percentage points compared with the previous year.In the whole year of 2018, the total loss of the pharmaceutical industry amounted to 4.03 billion yuan, a year-on-year increase of 13.5%.
In terms of total profit, China's pharmaceutical industry realized a total profit of 309.42 billion yuan from January to December 2018, up 9.5% year-on-year. As of January-February 2019 China's pharmaceutical industry total profit reached 48.26 billion yuan, up 4.2% year-on-year.
Statistics on the Number of Enterprises Above Scale in China's Pharmaceutical Industry in the First 2 Months of 2018-2019
Data Source: Compiled by Prospect Industry Research Institute
Statistics and Growth of Total Profit in China's Pharmaceutical Industry in the First 2 Months of 2018-2019
Data Source: Compiled by Prospect Industry Research Institute
(Remarks: the Jan-Jul. July total profit growth rate of 11.7%)
4+7 band purchasing landing accelerated
Chen Jinfu, deputy director of the State Medical Protection Bureau, introduced that since April 1, the 4+7 band purchasing of 11 pilot cities has been fully launched, and as of 24:00 on April 14, the total amount of purchases of the 25 selected varieties in the 11 pilot regions reached 438 million tablets and sticks, with a total amount of 533 million yuan, completing 27.31% of the total agreed procurement volume.
Chen Jinfu said, this figure should be said to exceed expectations, but also to eliminate the previous concerns, that is to say, the hospital to adopt or not, use or not. From the effect of the pilot, the pilot area of tumor, hepatitis B, hypertension, mental illness and other major diseases of patients with medication access to high-quality and inexpensive drugs, medical costs fell significantly.
Chen Jinfu said at the conference, the next step, will continue to solidly grasp the organization and implementation of the pilot work, including strengthening the pilot monitoring and supervision, guidance to the pilot areas to ensure the quality and supply of selected medicines, to promote the priority use of selected medicines, to enable patients to truly get the benefits of the reform pilot and the dividends; timely initiation of the pilot's assessment, summarize, and guide the improvement of the pilot policy; according to the pilot evaluation Based on the results of the pilot assessment, fully listen to the views of all parties, improve the policy and system of centralized bidding and procurement, and study and deploy the expansion of the pilot work.
Before that, the second round of band purchasing will be launched this summer the news reached the market.
However, the aforementioned business people believe that the first round of has not been fully implemented, and the second round of banded purchasing should not be launched soon. "There is also a need to assess and summarize the implementation results."
Industrial chain accelerates adjustment
As the 4+7 band purchasing is being implemented, both pharmaceutical companies and distribution companies are facing business adjustments, which can also be seen in the annual reports released by listed companies.
Shanghai Pharmaceutical described the impact of the pilot program of centralized purchasing of medicines by state organizations on distribution this way in its 2018 annual report: the commercial circulation area is subject to the double pressure on revenue and gross profit with the sharp decline in the winning bid price of medicines and the further concentration of suppliers.
"The first round of centralized procurement of varieties in the average price reduction of about 52%, which means that the amount of distribution will shrink to half of the previous. However, from the current point of view, the volume is not large, so the impact on the industry is small." The above circulation enterprise source told reporters.
The above circulation business people think: "This has both advantages and disadvantages for the circulation business, the good side is to speed up the industry concentration, companies can take the opportunity to enhance the share of the hospital market; the disadvantage is that the winning varieties of the distribution amount and gross profit have declined, which can only rely on the market share to make up for the enhancement of the market share, and the other is to do more of the high growth rate of the device, retail, and other high gross margins of the Business."
It is understood that with the implementation of the pharmaceutical separation, the out-of-hospital market has become the focus of attention of the pharmaceutical market. In addition to the circulation enterprises to force the retail segment, pharmaceutical companies have also increased the layout of the drug retail market.
According to media reports, on April 11, 2019 Hengrui Pharmaceutical Retail Strategic Customer Invitation was held in Lianyungang City, Jiangsu Province. A number of well-known domestic pharmacy chains participated in the event.
In this regard, a pharmaceutical listed company people to the reporter so interpreted, in the future, a lot of prescription drugs need to be sold through the pharmacy, so the establishment of cooperation with these companies should be a very common and normal practice in the industry.
"Compared with the in-hospital market, the price of products in the out-of-hospital market is not much affected by the policy." Shi Lichen, head of Beijing Dingshen Pharmaceutical Consulting and Management Center, said in an interview with Securities Daily.
In response to the drug companies to develop the out-of-hospital market, the above distribution company said to reporters, "We are now vigorously developing retail is to deal with the outflow of prescriptions, fertilizer, even if the outflow of prescriptions to our own pharmacies."
Force DTP pharmacy
It is worth mentioning that, with the approval of new drugs and imported drugs to speed up, specialized pharmacies have become the focus of the layout of the enterprise.
It is understood that the main bearers of hospital prescription outflow include DTP pharmacies and hospital side stores. The advantage of the hospital-side stores is that they are close to the hospital, so it is convenient for patients to buy medicines nearby, and they operate a wide range of products, but the services they provide are often limited. DTP pharmacies, on the other hand, mainly sell new and specialty drugs, with high gross profit margins and strong customer stickiness. At the same time, DTP pharmacies also have the function of chronic disease management to meet patients' long-term medication needs and provide more professional and considerate services to patients.
In its 2018 performance report, China Resources Pharmaceutical introduced that the company*** has 853 retail pharmacies and is actively developing innovative business models such as DTP and chronic disease management, and the company's DTP pharmacies have laid out 140 pharmacies, covering 66 cities.
Yifeng Pharmacy disclosed in its 2018 annual report that it will accelerate the pace of construction of stores around hospitals and DTP/DTC specialized pharmacies, and accelerate in-depth strategic cooperation with prescription drug manufacturers. Up to now, the company has built more than 20 DTP specialized pharmacies, operating 42 national negotiation-designated health insurance reimbursement varieties and nearly 200 hospital prescription varieties, and established DTP/DTC
strategic partnerships with nearly 80 suppliers.
In addition, including Liu Pharmaceutical Co. and Yixintang have added to their DTP pharmacies.
"A lot of new and chronic drugs are targeting the out-of-hospital market." Another large pharmaceutical distribution company said to the "Securities Daily" reporter, so far it is very hot, but the total amount is not very large, after all, the price is more expensive, not many people can afford to use, but the future of the country's support for innovative drugs more and more, it will become the company to make up for the decline in profits of the generic drugs a way.
However, an industry source told reporters, but whether DTP pharmacy can undertake this good, but also need to consider two important factors: the first is the problem of the source of prescriptions, prescriptions can only be issued by a doctor, if you can not get a prescription from the hospital, connected to the Internet hospital platform function, with the ability to prescription will be very important; the second is the ability of the professional pharmacy services, for prescription drugs, patients may need to For prescription drugs, patients may need to ask about contraindications, compounding specifications, etc., and professional service capabilities are the guarantee of medication safety. These two factors are also a test of the comprehensive ability of the DTP pharmacy.